HYPERTENSION:慢性肾病者尿钠水平与死亡呈正相关

2014-04-22 小田 译 医学论坛网

英国一项研究表明,在慢性肾病患者中,尿钠(UNa)排泄与其死亡具有相关性,钠排泄、蛋白尿和生存率减少具有累积关联性。研究数据支持慢性肾病患者减少饮食钠摄入,但钠摄入的目标量尚需进一步研究。研究论文4月14日在线发表于《高血压》(HYPERTENSION)杂志。 研究纳入来肾脏科就诊的成人患者,这些患者均有≥1次的24小时 UNa评估。收集其24小时 UNa指标并计算UNa与肌

英国一项研究表明,在慢性肾病患者中,尿钠(UNa)排泄与其死亡具有相关性,钠排泄、蛋白尿和生存率减少具有累积关联性。研究数据支持慢性肾病患者减少饮食钠摄入,但钠摄入的目标量尚需进一步研究。研究论文4月14日在线发表于《高血压》(HYPERTENSION)杂志。

研究纳入来肾脏科就诊的成人患者,这些患者均有≥1次的24小时 UNa评估。收集其24小时 UNa指标并计算UNa与肌酐比值,记录患者至肾移植或死亡的时间。

结果显示,平均估算肾小球滤过率为48 mL/min·1.73 m2的患者数为423例。需肾移植治疗和死亡的患者数分别为90例和102例。估算肾小球滤过率的平均降幅为每年−2.8 mL/min·1.73 m2 。平均随访时间为8.5年。死亡或需肾移植治疗患者的UNa排泄和UNa与肌酐比值显著升高,但这些参数与转归差的关联性并不独立于肾功能、年龄和蛋白尿而存在。当对蛋白尿进行分层后,UNa与肌酐比值是死亡的显著累积附加风险,即使在低水平的蛋白尿患者中也如此。和一些研究类似,低水平的UNa与危险无相关性。

原始出处:

McQuarrie EP, Traynor JP, Taylor AH, Freel EM, Fox JG, Jardine AG, Mark PB.Association Between Urinary Sodium, Creatinine, Albumin, and Long-Term Survival in Chronic Kidney Disease.Hypertension. 2014 Apr 14.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=34396, encodeId=e7793439691, content=降钠很重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3ykRSkuxjt93yc9tvDWfIQItrwiaKSCps5kyrTyDlwic2FgoCWe88wR3ZiaggKYGueDIp26zVgnbzriaQ/0, createdBy=89d71602869, createdName=sundong, createdTime=Tue Aug 04 19:25:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17345, encodeId=58dd1e34591, content=好文章,超赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Mon Mar 02 00:15:00 CST 2015, time=2015-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725593, encodeId=b0921e255935b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Dec 28 14:17:00 CST 2014, time=2014-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994502, encodeId=067a199450219, content=<a href='/topic/show?id=84326326141' target=_blank style='color:#2F92EE;'>#正相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63261, encryptionId=84326326141, topicName=正相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Aug 13 10:17:00 CST 2014, time=2014-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038488, encodeId=49572038488c7, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Jun 06 03:17:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501042, encodeId=dcae1501042c7, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Apr 24 00:17:00 CST 2014, time=2014-04-24, status=1, ipAttribution=)]
    2015-08-04 sundong

    降钠很重要

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=34396, encodeId=e7793439691, content=降钠很重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3ykRSkuxjt93yc9tvDWfIQItrwiaKSCps5kyrTyDlwic2FgoCWe88wR3ZiaggKYGueDIp26zVgnbzriaQ/0, createdBy=89d71602869, createdName=sundong, createdTime=Tue Aug 04 19:25:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17345, encodeId=58dd1e34591, content=好文章,超赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Mon Mar 02 00:15:00 CST 2015, time=2015-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725593, encodeId=b0921e255935b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Dec 28 14:17:00 CST 2014, time=2014-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994502, encodeId=067a199450219, content=<a href='/topic/show?id=84326326141' target=_blank style='color:#2F92EE;'>#正相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63261, encryptionId=84326326141, topicName=正相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Aug 13 10:17:00 CST 2014, time=2014-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038488, encodeId=49572038488c7, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Jun 06 03:17:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501042, encodeId=dcae1501042c7, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Apr 24 00:17:00 CST 2014, time=2014-04-24, status=1, ipAttribution=)]
    2015-03-02 xiaoai5777

    好文章,超赞

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=34396, encodeId=e7793439691, content=降钠很重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3ykRSkuxjt93yc9tvDWfIQItrwiaKSCps5kyrTyDlwic2FgoCWe88wR3ZiaggKYGueDIp26zVgnbzriaQ/0, createdBy=89d71602869, createdName=sundong, createdTime=Tue Aug 04 19:25:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17345, encodeId=58dd1e34591, content=好文章,超赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Mon Mar 02 00:15:00 CST 2015, time=2015-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725593, encodeId=b0921e255935b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Dec 28 14:17:00 CST 2014, time=2014-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994502, encodeId=067a199450219, content=<a href='/topic/show?id=84326326141' target=_blank style='color:#2F92EE;'>#正相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63261, encryptionId=84326326141, topicName=正相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Aug 13 10:17:00 CST 2014, time=2014-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038488, encodeId=49572038488c7, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Jun 06 03:17:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501042, encodeId=dcae1501042c7, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Apr 24 00:17:00 CST 2014, time=2014-04-24, status=1, ipAttribution=)]
    2014-12-28 feather89
  4. [GetPortalCommentsPageByObjectIdResponse(id=34396, encodeId=e7793439691, content=降钠很重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3ykRSkuxjt93yc9tvDWfIQItrwiaKSCps5kyrTyDlwic2FgoCWe88wR3ZiaggKYGueDIp26zVgnbzriaQ/0, createdBy=89d71602869, createdName=sundong, createdTime=Tue Aug 04 19:25:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17345, encodeId=58dd1e34591, content=好文章,超赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Mon Mar 02 00:15:00 CST 2015, time=2015-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725593, encodeId=b0921e255935b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Dec 28 14:17:00 CST 2014, time=2014-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994502, encodeId=067a199450219, content=<a href='/topic/show?id=84326326141' target=_blank style='color:#2F92EE;'>#正相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63261, encryptionId=84326326141, topicName=正相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Aug 13 10:17:00 CST 2014, time=2014-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038488, encodeId=49572038488c7, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Jun 06 03:17:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501042, encodeId=dcae1501042c7, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Apr 24 00:17:00 CST 2014, time=2014-04-24, status=1, ipAttribution=)]
    2014-08-13 zutt
  5. [GetPortalCommentsPageByObjectIdResponse(id=34396, encodeId=e7793439691, content=降钠很重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3ykRSkuxjt93yc9tvDWfIQItrwiaKSCps5kyrTyDlwic2FgoCWe88wR3ZiaggKYGueDIp26zVgnbzriaQ/0, createdBy=89d71602869, createdName=sundong, createdTime=Tue Aug 04 19:25:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17345, encodeId=58dd1e34591, content=好文章,超赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Mon Mar 02 00:15:00 CST 2015, time=2015-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725593, encodeId=b0921e255935b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Dec 28 14:17:00 CST 2014, time=2014-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994502, encodeId=067a199450219, content=<a href='/topic/show?id=84326326141' target=_blank style='color:#2F92EE;'>#正相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63261, encryptionId=84326326141, topicName=正相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Aug 13 10:17:00 CST 2014, time=2014-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038488, encodeId=49572038488c7, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Jun 06 03:17:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501042, encodeId=dcae1501042c7, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Apr 24 00:17:00 CST 2014, time=2014-04-24, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=34396, encodeId=e7793439691, content=降钠很重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3ykRSkuxjt93yc9tvDWfIQItrwiaKSCps5kyrTyDlwic2FgoCWe88wR3ZiaggKYGueDIp26zVgnbzriaQ/0, createdBy=89d71602869, createdName=sundong, createdTime=Tue Aug 04 19:25:00 CST 2015, time=2015-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17345, encodeId=58dd1e34591, content=好文章,超赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Mon Mar 02 00:15:00 CST 2015, time=2015-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725593, encodeId=b0921e255935b, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Dec 28 14:17:00 CST 2014, time=2014-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1994502, encodeId=067a199450219, content=<a href='/topic/show?id=84326326141' target=_blank style='color:#2F92EE;'>#正相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63261, encryptionId=84326326141, topicName=正相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Aug 13 10:17:00 CST 2014, time=2014-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038488, encodeId=49572038488c7, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Jun 06 03:17:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501042, encodeId=dcae1501042c7, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Thu Apr 24 00:17:00 CST 2014, time=2014-04-24, status=1, ipAttribution=)]

相关资讯

火山灰黏土或有助于治疗慢性肾病 副作用很小

慢性肾病已成为现代人健康的一大杀手,而现有的治疗药物会产生极大的副作用。德国科学家发现,火山灰形成的黏土如果用来制药,可能有助于治疗慢肾病。 当肾脏功能开始衰竭时,不能有效过滤掉血液中的磷酸盐,过多磷酸盐会进入血液形成磷酸钙沉积物,进而导致动脉硬化并引发心脏病和中风。为降低这一风险,慢性肾病患者需要服用磷酸盐结合剂。这种药物可以阻止肠道对磷酸盐的吸收,促使磷酸盐排出体外。但现有药物多为钙或铝

Neurology.:慢性肾病或为痴呆的独立危险因素

慢性肾病(CKD)被认为是未来卒中和亚临床血管疾病如脑小血管疾病的独立危险因素;肾脏和脑小血管有相似的解剖和生理特点,由内皮障碍导致的小血管病理可以解释二者之间的联系。而脑小血管疾病(CSVD主要通过影像学诊断,包括:腔隙性梗塞、腔隙、白质病变、血管周围间隙、脑微出血)和认知损害有关,且是血管性认知障碍的首因。 CKD与认知损害之间潜在的关系常常解释为CKD病人中较高

JCI:科学家揭示机体发生慢性肾病的分子信号通路

近日,来自西奈山医学院的研究者通过研究揭开了从慢性肾病开始发病到最后肾衰竭过程中的异常分子信号通。慢性肾病的预防和治疗是当今社会公众健康的一个重要问题。 研究者Erwin Bottinger博士表示,我们的目标就是阐明内皮细胞的线粒体氧化应激反应调节从血液到尿液的蛋白通过的分子机制,以及肾脏如何过滤那些废弃物的机理;相关成果为研究者开发治疗慢性肾病的新型靶向疗法提供了一定的希望和思路。 文章中

德探索慢性肾病治疗新方法

慢性肾病多因免疫系统“出错”所致,德国研究人员按照这一思路,探索利用一种新的疗法治疗慢性肾病,以达到更佳疗效。 慢性肾病是绝大多数肾脏疾病的临床统称,若不及时诊治,可发展成尿毒症。德国波恩大学医学院16日发表新闻公报说,研究人员发现,一种名为CX3C趋化因子的分子在肾病发展中扮演重要角色。 肾脏会产生很多CX3C趋化因子,它们与受体结合会导致肾脏中树突细胞增多,而树突细胞是启动、调控和维持免疫

NEJM:APOL1遗传变异与慢性肾病进展相关(AASK研究和CRIC研究)

在美国有大量的慢性肾病患者,与白人相比,黑人更容易转化成终末期肾病。为了研究不同民族人群慢性肾病的差异,全球320家单位发起了两个大型研究---AASK 研究和 CRIC研究。在这两个研究中,AASK(美国非裔慢性肾病和高血压研究)中,评估了693位患者慢性肾病合并高血压的黑人患者。在慢性肾衰队列研究(CRIC)研究中,评估了2955位患有慢性肾病的白人与黑人,其中46%伴有糖尿病。按照载脂蛋白1

银屑病与慢性肾病有关

研究人员首次声明称他们发现了中重度银屑病与慢性肾病(CKD)之间的一个联系。据费城宾夕法尼亚大学Perelman医学院皮肤病及流行病学助理教授Joel M. Gelfand和他的同事称,在一项匹配队列研究中,治疗记录取代了疾病的严重程度,重度银屑病病人CKD的发病率要比那些中等程度银屑病病人高将近两倍(校正后OR1.93 VS 0.99)。 在他们在线发表于BMJ杂志的研究中,他们称,CKD的风